WO1995021163A1 - Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor - Google Patents
Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor Download PDFInfo
- Publication number
- WO1995021163A1 WO1995021163A1 PCT/JP1995/000135 JP9500135W WO9521163A1 WO 1995021163 A1 WO1995021163 A1 WO 1995021163A1 JP 9500135 W JP9500135 W JP 9500135W WO 9521163 A1 WO9521163 A1 WO 9521163A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- salt
- formula
- general formula
- represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
- B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
- B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D47/00—Separating dispersed particles from gases, air or vapours by liquid as separating agent
- B01D47/02—Separating dispersed particles from gases, air or vapours by liquid as separating agent by passing the gas or air or vapour over or through a liquid bath
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D50/00—Combinations of methods or devices for separating particles from gases or vapours
- B01D50/60—Combinations of devices covered by groups B01D46/00 and B01D47/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
- B01D53/02—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by adsorption, e.g. preparative gas chromatography
- B01D53/04—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
- B01D53/0407—Constructional details of adsorbing systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
- B01D53/14—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28016—Particle form
- B01J20/28021—Hollow particles, e.g. hollow spheres, microspheres or cenospheres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28023—Fibres or filaments
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
- B60H3/00—Other air-treating devices
- B60H3/06—Filtering
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
- B60H3/00—Other air-treating devices
- B60H3/06—Filtering
- B60H3/0608—Filter arrangements in the air stream
- B60H3/0633—Filter arrangements in the air stream with provisions for regenerating or cleaning the filter element
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
- B60H3/00—Other air-treating devices
- B60H3/06—Filtering
- B60H3/0658—Filter elements specially adapted for their arrangement in vehicles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
- B60H3/00—Other air-treating devices
- B60H3/06—Filtering
- B60H2003/0691—Adsorption filters, e.g. activated carbon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a novel compound useful as an antibacterial agent and a bicyclic amide which is a synthetic intermediate thereof.
- Landscape technology a novel compound useful as an antibacterial agent and a bicyclic amide which is a synthetic intermediate thereof.
- JP-A-64-56673 discloses the following general formula:
- R represents a lower alkyl group, a halogeno lower alkyl group, a lower alkenyl group, a cycloalkyl group or a phenyl group which may have a substituent
- X represents a nitrogen atom or C—A.
- A represents a hydrogen atom or a halogen atom
- Y represents a hydrogen atom or a halogen atom
- Z represents the following formula
- R 2 , R 3 , R 4 and R 5 are two of which are bonded directly or via a lower alkyl chain to form a ring, the others represent a hydrogen atom, and n represents 0 or 1.
- R 2 and ⁇ are direct bonds.
- R 4 and R 5 in the above formula (A) are linked via an ethylene chain to form a ring. Is not disclosed.
- Ri is hydrogen, hydroxy, C, -C alkyl, -C 4 alkyne, oxo, halogen or optionally C, -C 4 alkyl and Z or C, 1 -C 4 alkanol, A good amino
- R 2 is azide, hydroxy, C! -C 4 alkoxy, Ci-C 4 alkoxycarbonyl, d—C 4 alkanol or optionally — C 4 alkyl and / or Ci—C 4 A is amino which may be substituted by an alkanoyl;
- R 3 is hydrogen or a carboxy protecting group
- n and p are each
- R represents a hydrogen atom or a carboxyl group
- a conventional pyridonecarboxylic acid derivative substituted with a bicyclic amino group such as the compound represented by the above general formula (A) or (B), Although useful as an antibacterial agent, its antibacterial activity, particularly in vivo (in vivo), is not always sufficient.
- the present invention has been completed as a result of various studies to develop a pyridonecarboxylic acid derivative with further enhanced antibacterial activity, especially in vivo.
- Pri is a pyridonecarboxylic acid residue
- A is a compound represented by the following formula (C) bonded to the 7-position or a position corresponding to the 7-position of the pyridonecarboxylic acid.
- R and R 2 are the same or different and each represents a hydrogen atom, a lower alkyl group or an amino protecting group
- R 3 and R 4 are the same or different
- Each represents a hydrogen atom, a halogen atom, a cyano group, a hydroxyl group, an oxo group, a lower alkoxy group or a lower alkyl group
- n represents an integer of 0 or 1.
- R, R 2 , R 3 , R 4 and n have the above-mentioned meanings.
- a pyridonecarboxylic acid residue represented by “P ri” means a group having a skeleton structure represented by the following formula (D) in a molecule.
- position 7 or equivalent position of pyridonecarboxylic acid Is the position of w in the above formula (D).
- the 7-position is represented by a pyrid [2,3_d].
- this means the 2-position in the case of a pyridonecarboxylic acid having a pyrimidine structure, this means the 2-position, and in the case of a pyridonecarboxylic acid having an ofloxacin structure, it means the 10-position.
- a pyridonecarboxylic acid derivative substituted with a bicyclic amino group represented by the following general formula (I-A), an ester thereof and a salt thereof are preferably provided. Is done.
- R 5 represents a lower alkyl group, a lower alkenyl group, a lower cycloalkyl group, a phenyl group, or a heterocyclic group (these groups may be further substituted); E or a nitrogen atom, where E is a hydrogen atom, or together with R 5 forms a bridge represented by —S—CH (CH 3 ) —, and T is C—Z Or a nitrogen atom, wherein Z represents a hydrogen atom, a halogen atom, a cyano group, a lower alkoxy group, a halogeno lower alkoxy group, a lower alkyl group or a halogeno lower alkyl group, or together with R 5
- X forms a bridge represented by — ⁇ -CH 2 —CH (CH 3 ) —, and X represents a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or an amino group which may be protected.
- the structural feature of the compound (I) of the present invention is that a specific bicyclic amino group represented by the formula (C) is selected as a substituent at the 7-position or a position equivalent to the 7-position of pyridonecarboxylic acid. I did it. Next, terms relating to substituents and the like in this specification will be described.
- halogen atom is not particularly limited, but fluorine, chlorine or bromine is preferred.
- Examples of the “lower alkenyl” include vinyl, aryl, 1-propenyl, and isopropenyl, and vinyl is preferable.
- “Lower cycloalkyl” includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, with cyclopropyl being preferred.
- Examples of “lower alkoxy” include methoxydiethoxy.
- the substituent of the "further substituted or unprotected lower alkenyl group” or “further optionally substituted lower cycloalkyl group” Is a halogen atom such as fluorine or chlorine.
- substituent in the “optionally substituted phenyl group” include, for example, halogen, lower alkyl, lower alkoxy, hydroxy, nitro, amino And the like.
- heterocyclic group for example, a heterocycle such as pyrrole, furan, thiophene, thiazole, isothiazole, oxazole, isoxazole, pyrazole, imidabur, pyridine, pyridazine, pyrimidine, virazine, etc.
- heterocyclic groups include 5- or 6-membered heterocyclic groups containing N, ⁇ , or S as atoms, and these heterocyclic groups include, for example, halogen, lower alkyl, lower alkoxy, hydroxy, nitro, amino and the like. It may be further substituted.
- protecting group and "amino protecting group” in the “optionally protected amino group” include ordinary deprotecting groups such as hydrolysis or hydrogenolysis. Any substance that can be easily desorbed by the reaction without substantially affecting other structural parts can be employed.
- Examples of readily hydrolyzable amino protecting groups that can be easily removed by hydrolysis include ethoxycarbonyl tB0c, butoxycarbonyl, benzyloxycarbonyl, ⁇ -methoxybenzyloxycarboxy.
- Oxycarbonyl groups such as benzyl, vinyloxycarbonyl, S- (p-toluenesulfonyl) ethoxycarbonyl; acyl groups such as formyl, acetyl, and trifluoroacetyl; 0-ditrophenylsulfenyl, trimethylsilyl, Tetrahydroviranyl, diphenylphosphinyl and the like.
- Examples of the easily hydrolyzable amino-protecting group which is easily eliminated by hydrogenolysis include, for example, an arylsulfonyl group such as p-toluenesulfonyl; and a phenyl such as benzyl, trityl and benzyloxymethyl. Is a methyl group substituted by benzyloxy; arylmethoxycarbonyl groups such as benzyloxycarbonyl and 0-methoxybenzyloxycarbonyl;,,, trichloroethynoxycarbonyl, ⁇ -ethoxyethoxycarbonyl And a halogenoethoxycarbonyl group.
- esters those which can be converted to the free carboxylic acid form (I) of the present invention by being eliminated by chemical means or enzymatic means are suitable.
- Esters which can be converted into the corresponding free-form ruponic acid forms by chemical means such as hydrolysis include lower alkyl esters such as methyl esters and ethyl esters.
- Esters that can be converted to the corresponding free carboxylic acid form not only by chemical means but also by enzymatic means include, for example, acetomethyl ester, 1-acetoxityl ester, and bivaloylodimethyl ester Lower Al-Nyloxy Lower Alkyl esters; lower alkoxycarbonyloxy lower alkyl esters such as 1-ethoxycarbonyloxyethyl ester; aminoethyl esters such as 2-dimethylaminoethyl ester and 2-((1-piperidinyl) ethyl ester; 3-butyrolactonyl ester, coryne ester, phthalidyl ester, (5-methyl-2-oxo-1,3
- salt of the compound (I) of the present invention a pharmaceutically acceptable salt is particularly preferred, and trifluoroacetic acid, acetic acid, lactic acid, succinic acid, methanesulfonic acid, maleic acid, malonic acid, gluconic acid, aspartic acid and glutamic acid are preferable.
- Salts with organic acids such as amino acids such as acid; salts with inorganic acids such as hydrochloric acid and phosphoric acid; metal salts such as sodium salt, potassium salt, zinc salt and silver salt; ammonium salts; Examples thereof include salts with organic bases such as trimethylamine, triethylamine, N-methylmorpholine, and the like.
- Examples of the salt of the compound of the present invention (IE) useful as an intermediate include salts with inorganic acids such as hydrochloric acid and sulfuric acid; and organic acids such as formic acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, and p-toluenesulfonic acid. Salts.
- the compounds (I) and (M) of the present invention sometimes exist as hydrates and solvates, and also exist as optically active isomers and stereoisomers (cis- and trans-forms). Sometimes. These compounds are also included in the present invention.
- R 5 , G, T, X, Y and n have the above-mentioned meanings.
- R 5 ′ is a cyclopropyl group, a 2,4-difluorophenyl group or a t_butyl group which may be substituted by fluorine
- X ′ is a hydrogen atom, a halogen atom or an amino group
- T ' is CH, CF, CCC - 0CH 3 , a C-0CHF 2 or nitrogen atom
- Pri has the meaning described above, and L is a leaving group bonded to Pri at the 7-position or the position corresponding to the 7-position of Pri. (However, the carboxyl group and the oxo group present in the pyridonecarboxylic acid residue represented by Pri may form a hydrogen chelate bond between these groups.)
- R>, R 2 , R 3 , R 4 and n have the above-mentioned meanings.
- the product When a boron chelate moiety is present in the product by reacting it with a bicyclic amide compound represented by the following formula, the product can be easily produced by hydrolyzing it.
- the leaving group L in the general formula (H) includes, for example, a halogen atom, a lower alkoxy group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a lower alkylsulfonyloxy group, an arylsulfonyloxy group, etc.
- a halogen atom such as fluorine-chlorine is preferable.
- the compound (I) and the compound (IE) are reacted in an inert solvent at 10 to 180 ° C, preferably 20 to 130 ° C, preferably for 10 minutes to 24 hours. Can be carried out by stirring for 30 minutes to 3 hours.
- Solvents include water, methanol, ethanol, acetonitrile, Room temperature, pyridine, dimethylformamide, dimethylsulfoxide, 1-methyl-2-pyrrolidone, and the like. These solvents are used alone or in the form of a mixture.
- Acid acceptors include, for example, organic bases such as triethylamine, 1,8-diazabicyclo [5.4.0] —7-ndenecene (DBU), pyridine, quinoline, picolin, and the like.
- organic bases such as triethylamine, 1,8-diazabicyclo [5.4.0] —7-ndenecene (DBU), pyridine, quinoline, picolin, and the like.
- Inorganic bases such as sodium, potassium hydroxide, sodium carbonate, carbon dioxide lime, sodium hydrogen carbonate, hydrogen carbonate lime and the like are preferred.
- Compound (I) is known or can be produced according to a known method.
- the bicyclic amine compounds (II) are all novel, and their production methods will be described later.
- the carboxylic acid form can also be produced by subjecting a compound represented by the following general formula (IV) to a hydrolysis reaction.
- u represents a group that can be converted to a carboxyl group by hydrolysis, and R 2 , R 3 , R 4 , R 5 , n, G, D, X, and D have the above-mentioned meanings]
- examples of U which can be converted into a carboxyl group include, for example, ester, cyano, amide, amidino, or a group represented by the formula —C (—NH) - ⁇ —lower alkyl.
- the hydrolysis reaction can be carried out by bringing the compound (W) into contact with water in an appropriate solvent. This reaction is usually carried out in the presence of a catalyst such as an acid or a base in the sense of accelerating the reaction.
- a catalyst such as an acid or a base in the sense of accelerating the reaction.
- the acid catalyst include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, and organic acids such as acetic acid, trifluoroacetic acid, formic acid, and p-toluenesulfonic acid.
- the base catalyst include metal hydroxides such as sodium hydroxide and barium hydroxide, carbonates such as sodium carbonate and potassium carbonate, and sodium acetate.
- a solvent water is usually used, but a water-miscible organic solvent such as ethanol, ethylene glycol dimethyl ether, benzene, or dioxane is used together with water depending on the properties of the compound (1). , 0 to 150 ° C, preferably 30 to 100 ° C. This reaction can also be carried out by directly heating compound (IV) in the presence of the aforementioned acid and then adding water.
- a water-miscible organic solvent such as ethanol, ethylene glycol dimethyl ether, benzene, or dioxane
- L ′ is a leaving group
- R 5 ′′ is a lower alkyl group, a lower alkenyl group, a lower cycloalkyl group, a phenyl group, a heterocyclic group (these groups may be further substituted)
- G ′ represents CH or a nitrogen atom
- T ′′ represents C—Z or a nitrogen atom, wherein Z has the above-mentioned meaning
- R 6 is a lower alkyl group, an aryl group or A benzyl group
- R 2 , R 3 , R 4 , n, X and D have the same meaning as described above).
- the leaving group L ′ here is preferably a group as described above for the leaving group L, particularly a halogen atom such as fluorine or chlorine.
- a base such as sodium carbonate, sodium hydride, and potassium t-butoxy
- a base such as sodium carbonate, sodium hydride, and potassium t-butoxy
- This is carried out by stirring a mixture of compound (V) and a solvent at 30 to 150 ° C, preferably 30 to 100 ° C for 1 to 6 hours in the presence of side, potassium fluoride, or the like. can do.
- the solvent ethanol, dioxane, tetrahydrofuran, dimethylformamide, dimethylsulfoxide and the like are suitable.
- reaction formula (1) The compound (V) used as a raw material is also novel and can be produced, for example, according to the following reaction formula (1). Reaction formula (1)
- R 6 ′ is a hydrogen atom or has the same meaning as R 6 above, and R and R 8 are the same or different and each represent a lower alkyl group, and R,, R 2, R 3, R 4, R 5 ", R 6 , n, G ′, D ′′, D, X, L and L ′ have the above-mentioned meanings.
- the present invention produced by any one of the above (a), (b) or (c)
- the elimination reaction of the amino protecting group by hydrolysis can be carried out in the same manner as in the method described in the above method (b).
- the elimination reaction of the amino protecting group by hydrogenolysis is advantageous by treating the compound (I) of the present invention having an easily hydrolyzable amino protecting group with hydrogen gas in a solvent in the presence of a catalyst.
- the compound can be converted to a compound of the present invention in which the amino protecting group is a hydrogen atom.
- the catalyst that can be used in this reaction include platinum, palladium, and Raney nickel.
- the solvent for example, ethylene glycol, dioxane, dimethylformamide, ethanol, acetic acid, water and the like can be used. This reaction can be carried out at 60 ° C or less, usually at room temperature.
- the easily hydrolyzable amino-protecting group is benzyl, trityl, benzyloxycarbonyl, p-toluenesulfonyl, etc.
- a protecting group can be treated with sodium metal in liquid ammonia at 50 to 120 ° C. It can also be desorbed.
- the compound (HI) used as a raw material is, for example, a compound represented by the following general formula (VI) R 2 —
- R 9 and R 10 each have the same meaning as or can be converted to R 3 and R 4 , RH is an amino protecting group, R 2 and n Has the above meaning)
- the protecting group of the compound represented by is removed and converted to a hydrogen atom, and R 9 and / or R ,.
- R 9 and / or R When is a group that can be converted into R 3 and Z or R 4 , R 9 and or. Can be produced by converting into R 3 and / or R 4 .
- Amino protecting group R! examples of the, include the readily hydrolyzable amino-protecting group and the easily hydrolyzable amino-protecting group described above.
- R 2 of the compound (VI) is an amino protecting group
- the amino protecting group of RH should be different in character from the amino protecting group of R! Or R 2.
- RH is preferably selected from a readily hydrolyzable amino protecting group such as benzyl ditrityl. Is done.
- This elimination reaction can be carried out by subjecting compound (VI) to a hydrogenolysis reaction or a hydrolysis reaction described above.
- R 9 and R 10 “a group that can be converted to R 3 and R 4 ” Examples include methanesulfonyloxy, p-toluenesulfonyloxy, benzyloxy, carboxy, carbamoyl, hydroxyminomethyl, benzylidene, cyclic acetal, dithioacetal, and the like.
- Methanesulfonyloxyp-toluenesulfonyloxy can be converted to a halogen atom, a cyano group or a lower alkoxy group as R 3 or R 4 by nucleophilic or substitution reactions.
- Benzoxy can be converted to a hydroxyl group as R 3 or by a hydrogenolysis or hydrolysis reaction, and carboxy is converted to an acid halide, followed by a Wilkinson complex ⁇ RhCl [P (C 6 H 5 ) 3 ] 3 ⁇ Can be converted to a halogen atom as R 3 or R 4 .
- carbamoyldihydroxyaminomethyl can be converted to a cyano group as R 3 or R 4 by treatment with thionyl chloride or chlorosulfonyl isocyanate, and benzylidene is converted to a cyclic acetal by oxidation.
- the compound (VI) is also novel, for example, Examples I to! It can be produced by the method described in ⁇ or a method analogous thereto.
- the compound (I) of the present invention and its intermediate compound (II) thus produced can be isolated and purified according to a conventional method. These compounds can be obtained in the form of salts, free forms, or hydrates depending on the conditions of isolation and purification. Compounds can be prepared.
- stereoisomers of the compounds (I) and ( ⁇ ) of the present invention can be prepared by a conventional method, for example, for example, they can be separated from each other by a fractional crystallization method, a chromatography method, or the like, and the optically active substance can be isolated by applying a known optical resolution method.
- the thus-obtained compound (I) of the present invention and salts thereof are all novel compounds, exhibit excellent antibacterial activity, and are valuable as antibacterial agents.
- the compound (I) of the present invention and salts thereof can be used not only as human and veterinary medicines but also as fish disease medicines, agricultural chemicals, food preservatives and the like.
- the ester form of the compound (I) of the present invention is valuable as a raw material for synthesizing the carboxylic acid form of the compound (I) of the present invention, but the ester form itself is easily converted into a carboxylic acid form in a living body. In some cases, it has the same action and effect as the carboxylic acid compound, and is also useful as an antibacterial agent.
- the compound (HI) of the present invention is useful as a direct intermediate of the compound (I) of the present invention.
- mice systemic infection (ED 5fl ; nig / kg) was as follows : Intraperitoneal injection of 5 x 10 3 viable bacteria (live bacteria) listed in Table 1 per Std-ddy male mouse (body weight: about 20 g) The test compound suspended in 0.4% carboxymethylcellulose was orally administered twice immediately after infection and 6 hours after infection. The survival rate of mice 7 days after infection was calculated by the Probit method.
- the control compound include piomidic acid, which is already commercially available as an excellent antibacterial agent, and 7_ (1-amino) having the following structure disclosed in Example 6 of the above-mentioned JP-A-64-56673. 3-Azabicyclo [3.1.0] hexar 3-yl) 1 1-Cyclopropyl-6,8-difluoro-1,4_dihydro ⁇ -4 4-oxoquinoline-3-carboxylic acid.
- Ph-F 2 2,4-diflurescent ⁇ -phenyl Me: methyl
- the compound (I) of the present invention exhibits excellent antibacterial activity both in vitro and in animal experiments. Especially in vivo-the compounds of the invention show better antibacterial activity than the comparative compounds.
- the compound (I) of the present invention has low toxicity and is useful as an antibacterial agent for mammals including humans, for prevention and treatment of bacterial diseases in mammals.
- the dosage varies depending on age, body weight, symptoms, administration route, etc. Generally, 5 mg to 5 g per day is administered once or several times. It is recommended that the drug be administered separately.
- the route of administration may be oral or parenteral.
- the compound (I) of the present invention may be administered to humans or the like as it is, but is usually administered in the form of a preparation prepared together with pharmaceutically acceptable additives.
- preparations include tablets, solutions, capsules, granules, granules, powders, syrups, injections, ointments and the like.
- These preparations can be produced using ordinary additives according to a conventional method.
- additives for oral use carriers or diluents which are commonly used in the pharmaceutical field such as starch, mannite, crystalline cellulose, potassium propyloxymethylcellulose, water, and ethanol and do not react with the compound of the present invention are used. Used.
- additives for injection include those commonly used in the field of injections, such as water, physiological saline, glucose solutions, and infusions.
- Example I! ⁇ relates to the method for producing the intermediate ( ⁇ )
- Examples 1 to 16 relate to the method for producing the target compound (I)
- Example A relates to the method for preparing the pharmaceutical preparation. This is an example.
- the obtained crude product was dissolved in 47 ml of formic acid, and 17 g of anhydrous acetic acid was added dropwise over 90 minutes under ice cooling. Add ice water, and add sodium hydroxide aqueous solution under ice cooling The solution was added for neutralization, and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography.
- (B) Dissolve 5.3 g of the compound obtained in (A) in 200 ml of tetrahydrofuran, add 7.1 g of triphenylphosphine, 5.2 g of getyl azodicarboxylate, and 7.4 g of diphenylphosphoryl azide in order. Stirred at room temperature for 48 hours. After the reaction solution was concentrated under reduced pressure, ethyl acetate and 10% hydrochloric acid were added, and the mixture was vigorously stirred, and then the aqueous layer was separated. A 20% aqueous sodium hydroxide solution was added to adjust the pH to 1, and extracted with chloroform.
- heptane 1.07 g, 1-cyclopropyl-1,6,7-difluoro-1,4, dihydro-1-8-methoxy-4-oxoquinoline-1,3-force rubonic acid—BF 2 —chelate 1.15 g and 0.68 g of triethylamine was added to 18 ml of dimethyl sulfoxide, and the mixture was stirred at room temperature for 16 hours. Water was added, the mixture was extracted with chloroform, and the solvent was distilled off. To the obtained residue, 300 ml of 80% ethanol water and 50 ml of triethylamine were added, and the mixture was refluxed for 3 hours.
- Example A Tablet manufacturing method
- the compound (I) of the present invention is useful as a pharmaceutical (antibacterial) for mammals including humans, and the compound (m) of the present invention is a direct intermediate for synthesizing the compound (I).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Mechanical Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Filtering Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES95907826T ES2173175T3 (en) | 1994-02-04 | 1995-02-02 | DERIVATIVE OF PYRIDONACARBOXILIC ACID REPLACED WITH A BICYCLE AMINO GROUP, ESTER OF THE SAME, SALT OF THE SAME, AND BICYCLE AMINA AS INTERMEDIATE FOR PREPARATION. |
JP7520498A JP2848538B2 (en) | 1994-02-04 | 1995-02-02 | Pyridonecarboxylic acid derivatives substituted with a bicyclic amino group, esters and salts thereof, and bicyclic amines as intermediates thereof |
DK95907826T DK0812838T3 (en) | 1994-02-04 | 1995-02-02 | Pyridonecarboxylic acid derivatives substituted with bicyclic amino group, esters and salts thereof, and bicyclic amine as intermediate |
US08/875,728 US5990106A (en) | 1994-02-04 | 1995-02-02 | Bicyclic amino group-substituted pyridonecarboxylic acid derivatives, esters thereof and salts thereof, and bicyclic amines useful as intermediates thereof |
EP95907826A EP0812838B1 (en) | 1994-02-04 | 1995-02-02 | Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor |
DE69526595T DE69526595T2 (en) | 1994-02-04 | 1995-02-02 | PYRIDONE CARBONIC ACID DERIVATIVES SUBSTITUTED BY BICYCLIC AMINO GROUP, THEIR ESTERS AND SALTS, AND BICYCLIC AMINE AS INTERMEDIATE PRODUCT THEREOF |
PT95907826T PT812838E (en) | 1994-02-04 | 1995-02-02 | DERIVED FROM PYRIDONACARBOXYL ACID REPLACED WITH THE AMINO BICYCLE GROUP ITS ESTER ITS BICYLIC SALT AND AMINE AS ITS INTERMEDIARY |
AT95907826T ATE216993T1 (en) | 1994-02-04 | 1995-02-02 | PYRIDONE CARBOXYLIC ACID DERIVATIVES SUBSTITUTED BY BICYCLIC AMINO GROUP, THEIR ESTERS AND SALTS, AND BICYCLIC AMINE AS AN INTERMEDIATE THEREOF |
AU15896/95A AU699636B2 (en) | 1994-02-04 | 1995-02-02 | Bicyclic amino group-substituted pyridonecarboxylic acid derivatives, esters thereof and salts thereof, and bicyclic amines useful as intermediates thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3317294 | 1994-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995021163A1 true WO1995021163A1 (en) | 1995-08-10 |
Family
ID=12379117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000135 WO1995021163A1 (en) | 1994-02-04 | 1995-02-02 | Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor |
Country Status (10)
Country | Link |
---|---|
US (1) | US5990106A (en) |
EP (1) | EP0812838B1 (en) |
JP (1) | JP2848538B2 (en) |
AT (1) | ATE216993T1 (en) |
AU (1) | AU699636B2 (en) |
DE (1) | DE69526595T2 (en) |
DK (1) | DK0812838T3 (en) |
ES (1) | ES2173175T3 (en) |
PT (1) | PT812838E (en) |
WO (1) | WO1995021163A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0705828A1 (en) * | 1994-10-04 | 1996-04-10 | Bayer Ag | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents |
EP0807630A1 (en) * | 1995-02-02 | 1997-11-19 | Daiichi Pharmaceutical Co., Ltd. | Heterocyclic compounds |
EP0924213A1 (en) * | 1996-09-27 | 1999-06-23 | Daiichi Pharmaceutical Co., Ltd. | Pyridobenzoxazine derivatives |
WO2008082009A3 (en) * | 2007-01-05 | 2008-12-11 | Daiichi Sankyo Co Ltd | Fused substituted aminopyrrolidine derivative |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6296821B1 (en) * | 1999-10-20 | 2001-10-02 | Allied Signal Inc. | Complex shaped fiber for particle and molecular filtration |
ATE298262T1 (en) * | 2000-01-27 | 2005-07-15 | Honeywell Int Inc | ANTIMICROBIAL FIBROUS MEDIUM |
JP2015029987A (en) * | 2013-08-07 | 2015-02-16 | 株式会社東芝 | Acid gas absorbent, acid gas removal method, and acid gas removal apparatus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015933A1 (en) * | 1992-12-30 | 1994-07-21 | Cheil Foods & Chemicals, Inc. | Novel pyridone carboxylic acid derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0022288A3 (en) * | 1979-07-06 | 1981-07-01 | Shell Internationale Researchmaatschappij B.V. | Method of sterilizing male anthers in plants, compositions and compounds suitable for use in such a method, and method of producing f1 hybrid seed |
JPH0676400B2 (en) * | 1987-08-25 | 1994-09-28 | 大日本製薬株式会社 | Novel pyridonecarboxylic acid derivative, its ester and its salt |
JP2844079B2 (en) * | 1988-05-23 | 1999-01-06 | 塩野義製薬株式会社 | Pyridonecarboxylic acid antibacterial agent |
IE66202B1 (en) * | 1989-08-16 | 1995-12-13 | Pfizer | Azabicyclo quinolone carboxylic acids |
EP0549857A1 (en) * | 1991-12-31 | 1993-07-07 | Korea Research Institute Of Chemical Technology | Antibacterial quinolone carboxylic acid derivatives |
-
1995
- 1995-02-02 DE DE69526595T patent/DE69526595T2/en not_active Expired - Fee Related
- 1995-02-02 AT AT95907826T patent/ATE216993T1/en not_active IP Right Cessation
- 1995-02-02 WO PCT/JP1995/000135 patent/WO1995021163A1/en active IP Right Grant
- 1995-02-02 AU AU15896/95A patent/AU699636B2/en not_active Ceased
- 1995-02-02 EP EP95907826A patent/EP0812838B1/en not_active Expired - Lifetime
- 1995-02-02 US US08/875,728 patent/US5990106A/en not_active Expired - Fee Related
- 1995-02-02 ES ES95907826T patent/ES2173175T3/en not_active Expired - Lifetime
- 1995-02-02 DK DK95907826T patent/DK0812838T3/en active
- 1995-02-02 PT PT95907826T patent/PT812838E/en unknown
- 1995-02-02 JP JP7520498A patent/JP2848538B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015933A1 (en) * | 1992-12-30 | 1994-07-21 | Cheil Foods & Chemicals, Inc. | Novel pyridone carboxylic acid derivatives |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0705828A1 (en) * | 1994-10-04 | 1996-04-10 | Bayer Ag | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents |
US5679689A (en) * | 1994-10-04 | 1997-10-21 | Bayer Aktiengesellschaft | Quinolone- and naphthyridonecarboxylic acid derivatives |
EP0807630A1 (en) * | 1995-02-02 | 1997-11-19 | Daiichi Pharmaceutical Co., Ltd. | Heterocyclic compounds |
EP0807630A4 (en) * | 1995-02-02 | 1998-05-13 | Daiichi Seiyaku Co | Heterocyclic compounds |
US5849757A (en) * | 1995-02-02 | 1998-12-15 | Daiichi Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivatives substituted by a bicyclic amino group as antibacterials |
EP0924213A1 (en) * | 1996-09-27 | 1999-06-23 | Daiichi Pharmaceutical Co., Ltd. | Pyridobenzoxazine derivatives |
EP0924213A4 (en) * | 1996-09-27 | 2002-10-23 | Daiichi Seiyaku Co | Pyridobenzoxazine derivatives |
WO2008082009A3 (en) * | 2007-01-05 | 2008-12-11 | Daiichi Sankyo Co Ltd | Fused substituted aminopyrrolidine derivative |
EP2540715A1 (en) | 2007-01-05 | 2013-01-02 | Daiichi Sankyo Company, Limited | Fused substituted aminopyrrolidine derivative |
US8618094B2 (en) | 2007-01-05 | 2013-12-31 | Daiichi Sankyo Company, Limited | Fused substituted aminopyrrolidine derivative |
KR101419085B1 (en) | 2007-01-05 | 2014-07-15 | 다이이찌 산쿄 가부시키가이샤 | Fused substituted aminopyrrolidine derivative |
Also Published As
Publication number | Publication date |
---|---|
EP0812838A1 (en) | 1997-12-17 |
US5990106A (en) | 1999-11-23 |
DE69526595T2 (en) | 2002-08-22 |
AU1589695A (en) | 1995-08-21 |
DK0812838T3 (en) | 2002-08-19 |
PT812838E (en) | 2002-10-31 |
EP0812838A4 (en) | 1998-05-20 |
AU699636B2 (en) | 1998-12-10 |
ATE216993T1 (en) | 2002-05-15 |
JP2848538B2 (en) | 1999-01-20 |
EP0812838B1 (en) | 2002-05-02 |
DE69526595D1 (en) | 2002-06-06 |
ES2173175T3 (en) | 2002-10-16 |
JPH10512800A (en) | 1998-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2938280C (en) | 4-amino-imidazoquinoline compounds | |
JP2844079B2 (en) | Pyridonecarboxylic acid antibacterial agent | |
KR102611856B1 (en) | Imidazopyridazine modulators of IL-12, IL-23, and/or IFN-alpha | |
HU194561B (en) | Process for preparing novel, aminopyrrolidinyl group-substituted 1,8-naphthyridine derivatives and pharmaceuticals comprising such compounds as active substance | |
HUT64520A (en) | Process forf producing of derivatives of 1,2-dihydro-2-oxopyridine and pharamceutical compositions containing them | |
JPH0543551A (en) | New 5-substituted quinolone derivative, its ester and salt | |
JP2021501179A (en) | Aminoimidazopyridazine as a kinase inhibitor | |
JP2022501334A (en) | Indazole carboxamide as a kinase inhibitor | |
JP2673937B2 (en) | 5-Amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative | |
WO1992012146A1 (en) | Pyridonecarboxylic acid derivative | |
WO1995021163A1 (en) | Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor | |
JPH02290870A (en) | Enantiomerically pure 7-(3-amino-1- pyrrolidinyl)-quinolone- and naphthyridonecarboxylic acid | |
EP0514268A1 (en) | Substituted amino acid azetidinyl pyridone derivatives, their preparation and use as medicines | |
JPS61137885A (en) | 1,8-naphthylidine derivative, its ester and salt | |
JP3012684B2 (en) | Thienoquinoline derivatives, thienonaphthyridine derivatives and their salts | |
JPH05345777A (en) | 7-@(3754/24)4,4-dialkyl-3-amino-substituted pyrrolidinyl)-quinolone-3-carboxylic acid derivative | |
JP2951726B2 (en) | Pyridonecarboxylic acid derivatives and synthetic intermediates thereof | |
JPH0635458B2 (en) | Pyridonecarboxylic acid derivatives, their esters and their salts | |
EP0216323A2 (en) | Quinolonecarboxylic acid derivatives and their preparation | |
KR100359151B1 (en) | Pyridonecarboxylic acid derivatives substituted with bicyclic amino groups, esters and salts thereof, and bicyclic amines which are intermediates thereof | |
WO1996001260A1 (en) | Pyridonecarboxylic acid derivative, ester thereof, salt thereof, and intermediate for synthesis of these compounds | |
JPH0586392B2 (en) | ||
KR100234546B1 (en) | Pyridonecarboxylic acid derivatives and their preparation | |
WO1996011194A1 (en) | Pyridonecarboxylic acid derivative and intermediate for the synthesis of the same | |
KR0139946B1 (en) | Pyridone carboxylic acid derivatives and method of production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95197535.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995907826 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2212226 Country of ref document: CA Ref document number: 2212226 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970705317 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08875728 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1995907826 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970705317 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995907826 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970705317 Country of ref document: KR |